Shares of Cullinan Therapeutics Inc. (CGEM) surged 5.01% on Thursday after the biopharmaceutical company reported better-than-expected earnings for the third quarter of 2024.
The company reported a quarterly adjusted loss of $0.69 per share, beating analysts' consensus estimate of a $0.81 loss per share. While Cullinan had no reported revenue for the quarter, its net loss of $40.56 million was narrower than anticipated. The earnings beat was driven by cost controls and operational efficiencies.
Analysts have been cautiously optimistic on Cullinan, with all 10 analysts covering the stock rating it a "buy" or "strong buy." The average 12-month price target for the stock is $30, reflecting potential upside from current levels. With the better-than-expected Q3 results, the Street may revise its estimates higher going forward.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。